ESMO 2024: Keytruda is key to first-line treatment of HER2+ mGEJ adenocarcinoma
Gastroesophageal junction carcinoma (GEJ) is a difficult-to-treat malignancy that constitutes a large minority of all gastric cancers. One of the…
Gastroesophageal junction carcinoma (GEJ) is a difficult-to-treat malignancy that constitutes a large minority of all gastric cancers. One of the…